Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its plaque psoriasis drug, Stelara for use in adolescents (12 years of age or older). The drug is approved for adults in this indication since 2009.
The company believes that the label expansion is a significant achievement as plaque psoriasis develops before the age of 20 years in approximately one-third of the patients. Moreover, the number of treatments available for adolescents is limited.
Patients are administered only four doses a year after two starter doses of Stelara, which has become a leading therapeutic option.
Shares of the company are up 18.4% so far this year, almost in line with the industry’s performance. The industry has gained 18.3% in the same time frame.
The latest approval for Stelara is based on data from a phase III study, which evaluated the subcutaneous administration of the drug in adolescent patients. The data showed that the drug achieved minimal psoriasis or clear skin in at least two-thirds of the patients. The safety data was also consistent with what was achieved in adult patients.
There are almost 7.5 million people suffering from psoriasis in the United States per the American Academy of Dermatology. Moreover, the National Center for Biotechnology Information stated that the majority of psoriasis patients suffer from plaque psoriasis. The numbers represent a huge opportunity for the drug following its label expansion..
Moreover, with this approval Stelara has gained an edge over competing drugs like AbbVie Inc.’s (ABBV - Free Report) Humira, Novartis AG’s Cosentyx and Celgene Corporation’s Otezla, which are only approved for adult plaque psoriasis patients. However, Pfizer Inc.’s (PFE - Free Report) Enbrel will compete with Stelara in the adolescent segment.
Johnson & Johnson carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Janssen, a subsidiary of Johnson & Johnson (JNJ - Free Report) , announced that the FDA has approved the label expansion of its plaque psoriasis drug, Stelara for use in adolescents (12 years of age or older). The drug is approved for adults in this indication since 2009.
The company believes that the label expansion is a significant achievement as plaque psoriasis develops before the age of 20 years in approximately one-third of the patients. Moreover, the number of treatments available for adolescents is limited.
Patients are administered only four doses a year after two starter doses of Stelara, which has become a leading therapeutic option.
Shares of the company are up 18.4% so far this year, almost in line with the industry’s performance. The industry has gained 18.3% in the same time frame.
The latest approval for Stelara is based on data from a phase III study, which evaluated the subcutaneous administration of the drug in adolescent patients. The data showed that the drug achieved minimal psoriasis or clear skin in at least two-thirds of the patients. The safety data was also consistent with what was achieved in adult patients.
There are almost 7.5 million people suffering from psoriasis in the United States per the American Academy of Dermatology. Moreover, the National Center for Biotechnology Information stated that the majority of psoriasis patients suffer from plaque psoriasis. The numbers represent a huge opportunity for the drug following its label expansion..
Moreover, with this approval Stelara has gained an edge over competing drugs like AbbVie Inc.’s (ABBV - Free Report) Humira, Novartis AG’s Cosentyx and Celgene Corporation’s Otezla, which are only approved for adult plaque psoriasis patients. However, Pfizer Inc.’s (PFE - Free Report) Enbrel will compete with Stelara in the adolescent segment.
Johnson & Johnson carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
5 Trades Could Profit "Big-League" from Trump Policies
If the stocks above spark your interest, wait until you look into companies primed to make substantial gains from Washington's changing course.
Today Zacks reveals 5 tickers that could benefit from new trends like streamlined drug approvals, tariffs, lower taxes, higher interest rates, and spending surges in defense and infrastructure.
See these buy recommendations now >>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on JNJ - FREE
Get the latest research report on PFE - FREE
Get the latest research report on ABBV - FREE